证券代码：688658 证券简称：悦康药业 公告编号：2026-006 悦康药业集团股份有限公司 关于控股股东所持公司部分股份被司法拍卖的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 悦康药业集团股份有限公司（以下简称"公司"或"悦康药业"）控股股东 阜阳京悦永顺信息咨询有限公司（以下简称"京悦永顺"）持有公司股份 153,740,120 股，占公司总股本的比例为 34.16%。截至本公告披露日，本次京悦 永顺持有的本公司 1,720,000 股无限售流通股股票将被司法拍卖。 （一）拍卖标的：京悦永顺持有的悦康药业 172 万股股票（证券名称：悦康 药业，证券代码：688658，证券性质：无限售流通股）。 1、拍卖时间：2026 年 3 月 16 日 10 时至 2026 年 3 月 17 日 10 时止（延时 除外） 2、拍卖地点：在北京市第二中级人民法院京东网司法拍卖网络平台（网址： http://sifa.jd.com/29 户名：北京市第二中级人民法院）上进行公开拍卖活动。 3、本次 ...

证券代码：688048 证券简称：长光华芯 公告编号：2026-005 苏州长光华芯光电技术股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性 公告 投资者保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 苏州华丰投资中心（有限合伙）（以下简称"苏州华丰"）权益变动情况 | 权益变动方向 | 比例增加□ | | 比例减少 | | --- | --- | --- | --- | | 权益变动前合计比例 | 18.38% | | | | 权益变动后合计比例 | 17.29% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否 | | | 是否触发强制要约收购义务 | 是□ | 否 | | 苏州英镭创业投资合伙企业（有限合伙）（以下简称"苏州英镭"）权益变 动情况 | 2.信息披露义务人信息 | | --- | | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | | 苏州华丰 | □ □ ...

证券代码：600821 证券简称：金开新能 公告编号：2026-015 金开新能源股份有限公司 重要内容提示： ● 回购股份价格：不超过 7.50 元/股（含），该价格不高于公司董事会审议通 过回购股份决议前 30 个交易日股票交易均价的 150%。 1、截至本公告披露日，公司董事、高级管理人员、控股股东、实际控制人未 来 3 个月、未来 6 个月无减持计划，如未来前述主体提出减持计划，相关方及公 司将根据相关规定及时履行信息披露义务。 2、截至本公告披露日，持股 5%以上的股东国开金融有限责任公司、通用技术 集团国际控股有限公司未回复公司问询，其所持公司股份可能在公司回购期间进 行减持，敬请投资者注意投资风险。 ● 相关风险提示： 1、因公司生产经营、财务状况、外部客观情况发生重大变化等原因，可能存 在根据规则变更或终止本次回购方案的风险。 2、本次回购股份用于注销，减少公司注册资本，本次回购预案需征询债权人 同意，存在债权人不同意而要求提前清偿债务或要求公司提供相应担保的风险。 3、存在后续监管部门对于上市公司股份回购颁布新的规定与要求，导致本回 ● 回购股份金额：不低于 5 亿元（含）且不超过 6 亿元 ...

编辑/宋霞 文/北京青年报记者 宋霞 一年一度的"多退少补"开始了！2025年度个税汇算清缴的办理时间为2026年3月1日至6月30日。 网警提醒您，所有退税业务，请通过个人所得税官方App操作，切勿点击陌生链接。警惕"代操作多退 税""人工退税绿色通道""税务稽查要求转账""诱导虚假填报"等骗局。切勿泄露账号密码等信息，税务 部门不会通过短信社交软件索要资料或要求转账，谨防上当受骗。 ...

也有一些研究机构视英国1月的公共财政状况为"谨慎乐观"，根本问题是财政盈余状况能否持续。"1月 的财政盈余部分原因是政府的一次性收入增长，如资本利得税等，这和英国国民因担心税收增加而抓紧 抛售资产相关，但这是不可持续的。"万神殿宏观经济咨询公司经济学家在评价英国最新的公共财政报 告时称。 更大的困难来自于经济增长的低迷。英国国家统计局数据显示，英国雇员的薪资增长已经在明显放缓。 2025年10-12月，英国雇员薪资同比增长4.2%，低于9-11月4.5%的增长水平。"展望秋季预算案，英国的 经济增长放缓可能再次扰乱财政前景，引发更多关于潜在增税的猜测。此次的关键驱动因素是预计移民 人数下降，这将减少政府未来的财政收入，并有可能在2029-30财年导致公共财政出现赤字。"毕马威英 国公司高级经济学家Dennis Tatarkov说。目前，主流市场研究机构对英国2026年的经济增长预期在1%左 右，低于2025年1.3%的增长水平。 英国影子财政大臣Mel Stride指出，英国经济增速低于潜在增长水平，这是高税收的副作用。英国工党 政府不断提高税收，对财政状况进行整固，但付出的代价是经济增长持续疲弱。 新华财经 ...

GRAHAM HOLDINGS COMPANY REPORTS 2025 AND FOURTH QUARTER EARNINGS ARLINGTON, VA - Graham Holdings Company (NYSE: GHC) today reported its financial results for the fourth quarter and full year of 2025. The Company also filed its Form 10-K today for the year ended December 31, 2025 with the Securities and Exchange Commission. Division Operating Results Exhibit 99.1 Contact: Wallace R. Cooney For Immediate Release (703) 345-6470 February 25, 2026 Revenue for 2025 was $4,911.6 million, up 3% from $4,790.9 millio ...

可孚医疗2025年三季报显示，前三季度公司主营收入23.98亿元，同比上升6.63%；归母净利润2.6亿 元，同比上升3.3%；扣非净利润2.22亿元，同比上升1.46%；其中2025年第三季度，公司单季度主营收 入9.02亿元，同比上升30.72%；单季度归母净利润9282.98万元，同比上升38.68%；单季度扣非净利润 8580.27万元，同比上升62.68%；负债率27.37%，投资收益1818.06万元，财务费用-377.36万元，毛利率 53.35%。可孚医疗（301087）主营业务：家用医疗器械的研发、生产、销售和服务。 该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为53.84。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 证券之星消息，截 ...

Core Insights - Tempus AI, Inc. reported a fourth-quarter 2025 adjusted loss of 4 cents per share, an improvement from a loss of 16 cents in the same quarter last year, but wider than the Zacks Consensus Estimate by 66.7% [1] - The company’s revenues for the fourth quarter reached $367.2 million, surpassing the Zacks Consensus Estimate by 0.1% and reflecting an 83% year-over-year increase [2][7] - Full-year 2025 revenues totaled $1.27 billion, marking an 83.3% increase compared to the previous year [2] Revenue Breakdown - In the fourth quarter, Diagnostics generated revenues of $266.9 million, a significant 121.6% increase year-over-year, with Oncology volume growing by 29% and Hereditary volume by 23% [3] - The Data and Applications segment reported sales of $100.4 million, up 25.1% year-over-year, driven by a 69.5% growth in Insights (data licensing) [3] Margin and Operating Performance - Gross profit for the fourth quarter was $237.7 million, up 94.7% from the previous year, with an adjusted gross margin expanding by 391 basis points to 64.7% [4] - Total adjusted operating expenses were $259 million, an increase of 83.8% year-over-year, leading to an operating loss of $21.3 million compared to a loss of $18.8 million in the prior year [4] Liquidity Position - At the end of the fourth quarter of 2025, the company had cash and cash equivalents of $604.8 million, up from $340.9 million at the end of the fourth quarter of 2024 [5] - Cumulative net cash used in investing activities was $398.3 million, compared to $130.4 million a year ago [5] Future Outlook - For full-year 2026, the company expects revenues to reach $1.59 billion, indicating nearly 25% annual growth, with the Zacks Consensus Estimate for revenues at $1.56 billion [6][7] - Adjusted EBITDA for 2026 is projected to be $65 million [8] Market Reaction - Following the earnings announcement, shares of Tempus AI declined by 3.7% in after-market trading, reflecting investor concerns over the reported quarterly operating loss [2]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting with competent advisors before making any financial decisions, particularly in the context of investments in complex instruments like cryptocurrencies and CFDs [1]. Group 1 - The website provides general news, personal analysis, and third-party materials intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as a recommendation or advice for investment actions [1]. - The accuracy and reliability of the information are not guaranteed, and users are cautioned against relying solely on the content provided [1]. Group 2 - The website includes information about cryptocurrencies, CFDs, and other financial instruments, highlighting their complexity and associated high risks [1]. - Users are encouraged to conduct their own research and fully understand the workings and risks of any financial instruments before investing [1].

Core Viewpoint - 20/20 BioLabs has launched its OneTest for Longevity, a blood test that integrates inflammatory biomarkers, dietary habits, and scientific research to provide personalized health insights, utilizing IBM's watsonx.ai technology [1][2][3] Group 1: Product Launch and Features - The OneTest for Longevity solution calculates and displays an individual's risk of chronic diseases such as diabetes, dementia, and cardiovascular disease, offering personalized dietary recommendations based on biomarker levels [2] - The platform leverages IBM's advanced AI capabilities, including the Granite 4.0 foundation models and the Docling toolkit, to analyze nutritional research and deliver evidence-based health insights [3][6] - The test is available for purchase and is conducted in CLIA-licensed and CAP-accredited labs, although it has not sought FDA approval [3][7] Group 2: Partnerships and Technology - 20/20 BioLabs has partnered with DAISource to enhance its AI-enabled health solutions, aiming to improve public health through scalable and secure technology [3] - IBM's role is as an information technology provider, focusing on supporting enterprises with secure workloads in various sectors, including healthcare [4] Group 3: Company Background and Market Position - 20/20 BioLabs is an early market leader in laboratory-based blood tests for early detection and prevention of cancers and chronic diseases, with its stock listed on Nasdaq under the ticker symbol "AIDX" since February 19, 2026 [5][6] - The company also operates a Clinical Laboratory Innovation Accelerator (CLIAx) to assist overseas diagnostics startups in launching lab tests in the U.S. [8]